Muayqil Taim, Camicioli Richard
Division of Neurology, King Saud University, Riyadh, Saudi Arabia.
Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):546-72. doi: 10.1159/000343479. Epub 2012 Nov 23.
N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination.
To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI.
In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded randomized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes.
Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit.
Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made.
N-甲基-D-天冬氨酸拮抗剂(美金刚)和胆碱酯酶抑制剂(ChEIs)是仅有的两类被批准用于治疗痴呆症的药物;本文探讨联合使用这两种治疗方法的证据。
确定与单用美金刚或ChEIs进行单药治疗相比,联合使用美金刚和ChEIs治疗痴呆症的疗效和安全性。
2012年3月,我们系统检索了MEDLINE/PubMed、EMBASE、Cochrane图书馆和灰色文献数据库。除病例系列或报告外,所有研究类型均被纳入,这些病例系列或报告研究了各种痴呆症中联合治疗与单药治疗的情况。仅对双盲随机对照试验(RCT)的数据进行汇总;平均差和标准化平均差用于确定效应量。
本综述纳入了13项研究;3项为双盲RCT,共有971例阿尔茨海默病(AD)患者,被纳入荟萃分析。未发现主要针对其他痴呆症联合治疗的论文。在荟萃分析中,中度至重度AD患者在认知量表(0.45 - 0.52;p < 0.0001)、功能结局量表(0.23 - 0.3;p < 0.01)和神经精神科问卷(3.7 - 4.4;p < 0.0001)方面,联合治疗显示出虽小但具有统计学意义的效应量优势。在开放标签研究中,6项中有3项显示出益处,纳入的4项队列研究也是如此。然而,后两种研究设计中存在的高偏倚风险限制了得出任何关于益处的结论。
尽管在中度至重度AD中联合治疗显示出具有统计学意义的变化,但量表和患者特征存在异质性。然而,尚不清楚联合治疗是否能实现具有临床意义的结果。在能够推荐联合治疗之前,还需要更多的研究。